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Genome-wide association studies (GWASs) have proven highly effective, identifying hundreds of associ-
ations across numerous complex diseases. These studies typically test hundreds of thousands of variations
and identify hundreds of potential associations. However, to date, follow-up attempts have generally only
concentrated on just the few most signiﬁcant initial associations, leaving the majority of true associations
in any GWAS study without replication. Here, we present a substantially more comprehensive follow-up of
the ﬁrst genome-wide association screen performed in multiple sclerosis (MS), a complex genetic disease
with central nervous system inﬂammation. We genotyped approximately 30 000 single-nucleotide polymorph-
isms (SNPs) that demonstrated mild-to-moderate levels of signiﬁcance (P   0.10) in the initial GWAS in an
independent set of 1343 MS cases and 1379 controls. We further replicated several of the most signiﬁcant
ﬁndings in another independent data set of 2164 MS cases and 2016 controls. We ﬁnd considerable evidence
for a number of novel susceptibility loci including KIF21B [rs12122721, combined P 5 6.56 3 10
210, odds ratio
(OR) 5 1.22] and TMEM39A (rs1132200, P 5 3.09 3 10
28,O R5 1.24), both of which meet genome-wide signiﬁ-
cance. Both of these loci were overlooked in the initial replication, despite being among the top 3000 (1%)
SNP hits in the original screen.
INTRODUCTION
Multiple sclerosis (MS, MIM 126200) is an inﬂammatory,
demyelinating disease of the central nervous system (CNS),
thought to be mediated by an autoimmune process. It affects
over 2 million individuals world-wide. The disease is character-
ized by mononuclear cell inﬁltration in the CNS associated with
demyelination leading to a spectrum of symptoms and disability
withinaffected individuals.MSismostcommon inyoungadults
and affects women two tothree times more frequently than men.
Family and twin studies have long shown evidence for a strong
geneticcomponentunderlyingtheetiologyofMS.Untilrecently,
the major histocompatibility complex (MHC) was the only
universally accepted genetic locus associated with MS.
In 2007, we reported the ﬁrst genome-wide association study
(GWAS) for MS susceptibility. In this GWAS, we screened 931
trio families (an affected individual and both parents)
with 334 923 single-nucleotide polymorphisms (SNPs) and
followed-up110ofthemostpromisingassociationsinadditional
cases (n ¼ 2322), controls (n ¼ 5418) and trio families (n ¼
609). This ﬁrst-pass follow-up resulted in the identiﬁcation of
three strongly associated SNPs outside of the MHC, namely
rs6897932 in the interleukin-7 receptor a gene (IL7RA) and
both rs12722489 and rs2104286 within the interleukin-2 recep-
tor a gene (IL2RA) (1). These associations were replicated by
a number of groups (2–5) and further reﬁned in subsequent ana-
lyses (6). The GWAS also identiﬁed highly suggestive associ-
ations with variations in CLEC16A and CD58, both of which
havesubsequentlybeenconﬁrmed,alongwithothergenesident-
iﬁed through additional MS GWAS and restricted follow-up
efforts (e.g. TNFRSF1A, IRF8, CD6, TYK2, CD226 and
CYB27B1) (7–14). These genes are now the focus of multiple
ongoing studies to conﬁrm and understand their potential invol-
vement in MS susceptibility.
Statistically we would expect the pool of moderately signiﬁ-
cant GWAS results to be enriched for genuine associations. To
more comprehensively test for additional MS-associated loci,
we examined approximately 30 000 SNPs, whose initial
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GWAS, in an independent data set.
RESULTS
In Stage 1, we obtained genotype data on 30 915 SNPs in 1488
cases and 3710 controls. Following extensive quality control
(QC), we were ultimately able to utilize 29 561 SNPs in 1343
cases and 3577 controls for association with MS. This data set
gave us 80% maximum potential power to detect risk odds
ratio (OR) of 1.25, accepting a type 1 error rate of 0.001 (Sup-
plementary Material, Fig. S1) (15). There were 85 SNPs,
outsideoftheMHC(i.e.29–34 Mbonchromosome6),demon-
strating high levels of signiﬁcance (P   0.001) (Table 1).
Detailed analysis of SNPs within the broader MHC is the
focus of a separate parallel project. As the SNPs selected for
Stage 1 were chosen without consideration of linkage disequili-
brium(LD),thereareanumberofSNPswithP-values  0.0001
thatareinrelativelystrongLDwitheachotherandthereforethe
signiﬁcant SNPs do not represent 85 independent loci. As
expected, there are a number of Stage 1 top hits in previously
identiﬁed MS genes, including CLEC16A (1,7), CD58 (1,8),
IRF8(11)andMMEL1(M.B.,unpublisheddata).Asistypically
the case in replication studies, previous top hits have shifted
ranking in subsequent follow-up experiments. Our study is no
exception, as the association P-values with arguably the two
most notable genes, IL2RA (rs2104286, P ¼ 1.89   10
22)
and IL7RA (rs6897932, P ¼ 1.03   10
22), fall just below our
arbitrary P-value cutoff (P , 1.0   10
24) for inclusion in
Table 1 (see Supplementary Material, Table S1 for results of
the remaining 29 447 SNPs analyzed in Stage 1).
Following our analysis of the Stage 1 follow-up, we choose a
smaller subset of SNPs for further replication in an independent
dataset.Theresultsofthe19SNPsgenotyped(SequenomMas-
sARRAY iPLEX) and analyzed for Stage 2(20 SNPs were gen-
otyped, with 1 failing QC) are presented in Table 2. Eight of
these SNPs demonstrated further replication (P   0.05, with
consistent OR) in this independent data set. A combined analy-
sis for these 19 SNPs using data from the original screen and
both Stage 1 and Stage 2 included 931 Trios, 3507 cases and
8024 controls. Five SNPs meet a conservative estimate of
genome-wide signiﬁcance using a Bonferroni correction
(P-value cutoff 1.49   10
27) considering the 334 923 indepen-
dent tests from the original GWAS screen (Table 2). Further-
more, 4/5 SNPs were signiﬁcant in each of the independent
data sets. These four SNPs lie within or nearby KIF21B (on
chromosome 1), TMEM39A (on chromosome 3), C16orf75
and PRM1 (both on chromosome 16). However, the two SNPs
on chromosome 16 (rs12922090 and rs243315) near
C16orf75 and PRM1 are in very strong LD (D0 ¼ 0.99, r
2 ¼
0.82). We also performed conditional logistic regression on
these 19 SNPs conditioning on the HLA-DRB1 1501 tag
(rs3135388); interestingly, the three SNPs (rs12922090,
rs243315 and rs12927773) on chromosome 16 show slightly
more signiﬁcance in the HLA conditional analysis (Table 2).
DISCUSSION
We ﬁnd considerable evidence for several new MS suscepti-
bility loci including KIF21B (rs12122721, combined P ¼
6.56   10
210,O R¼ 0.82), TMEM39A (rs1132200, combined
P ¼ 3.09   10
28,O R ¼ 0.80) and PRM1 (rs243315, com-
bined P ¼ 1.07   10
27,O R ¼ 0.83), all of which have
demonstrated moderate-to-strong signiﬁcance in each stage
of our analyses and furthermore meet genome-wide signiﬁ-
cance using a stringent Bonferroni correction.
We have successfully identiﬁed novel loci for MS through
more detailed examination of results from a large ﬁrst-
generation GWAS. Interestingly, in the original GWAS, the
SNPs in KIF21B, TMEM39A and PRM1, although relatively
signiﬁcant in the more powerful case/control analysis
[Cochran–Mantel–Haenszel (CMH) P-value ranks between
0.3 and 4.2%], failed to rise to the top of the more limited
family-based analysis [the most signiﬁcant SNP
(rs12122721) had a transmission disequilibrium test (TDT)
P-value rank of 28.9%] (Tables 1 and 3). Furthermore, these
SNPs were among the top P-values (CMH P-value ranks
between 0.4 and 2.1%) in a recent meta-analysis of three
GWASs (11) (Table 3). These overall results clearly demon-
strate that additional true susceptibility loci are likely to be
buried beneath the top association results from GWAS (and
even meta-analyses of GWAS), and subsequently overlooked
in the rush to follow up the top hits. Testing only the ‘top
hits’ is often the result of the limited availability of resources
after conducting such a massive initial screening experiment.
Our data suggest that it is imperative to perform a more com-
prehensive follow-up study in the pursuit of identifying all loci
contributing to the genetic load for a given complex disease.
Furthermore, of the top Stage 1 results (P   0.001), the
average original GWAS P-value ranking of these SNPs is
approximately 40 000 for the CMH test (most signiﬁcant SNP
ranking 177, least signiﬁcant SNP ranking 319 841) and
approximately 69 000 for the TDT test (most signiﬁcant SNP
ranking194, least signiﬁcant SNP ranking 308 800). Approxi-
mately one-third (29/85) of the most signiﬁcant non-MHC
SNPs in Stage 1 (Table 1) had original GWAS P-values
,0.10 in both the TDT and CMH tests, with only two of
these SNPs further replicating in Stage 2 (rs11583328 and
rs10469900) (Table 2). We extended this examination by
ranking the three SNPs meeting genome-wide signiﬁcance
(i.e. within or nearby KIF21B, TMEM39A and PRM1) along
with the most signiﬁcant SNPs from the original GWAS (or
in the case of IL2RA where rs2104286 has been indicated as
the primary association (6)) and from other subsequently ident-
iﬁedMSsusceptibilitylociwithvaryinglevelsofconﬁdence.In
addition, we examined the rank of these SNPs in a recent
meta-analysis (Table 3). The original P-values of the three
newly identiﬁed loci were similar to those P-values seen in
the other conﬁrmed loci. Furthermore, each of these SNPs
was mildly to moderately signiﬁcant in the meta-analysis, but
as in the initial GWAS follow-up, these loci fall far
enough from the top that they are not initially selected for
limited follow-up. It follows that there may be other
yet-to-be-conﬁrmed loci within this same range of the data. It
is also noteworthy to highlight the robustness of the CMH test
compared with the TDT in identifying all of these loci in the
original screen. This may in part be related to the gain in
power due to the additional samples used in the CMH analysis.
The new MS loci identiﬁed in this study are functionally
interesting. KIF21B is a plus end-directed kinesin-like
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CHR SNP A1 A2 BP Gene Original GWAS P-value (rank) MAF OR L95 U95 P-value HLA conditional
P-value TDT Test CMH Test
6 rs3135388
a A G 32521029 HLA-DRA NA NA 0.19 3.18 2.77 3.64 1.34   10
262 NA
16 rs7184083 A G 11135415 CLEC16A 3.37   10
22 (12 626) 1.51   10
22 (6818) 0.35 1.27 1.16 1.40 3.68   10
27 3.66   10
27
16 rs6498169
b G A 11156830 CLEC16A 2.91   10
22 (10 940) 6.51   10
23 (3363) 0.35 1.26 1.15 1.38 1.34   10
26 1.51   10
26
16 rs181694
c T C 11292330 PRM1 0.35 (122 995) 1.79   10
22 (7915) 0.20 0.75 0.67 0.84 1.36   10
26 2.83   10
27
16 rs243315
d T C 11292512 PRM1 0.47 (160 855) 3.42   10
22 (13 992) 0.20 0.75 0.67 0.84 1.51   10
26 3.20   10
27
16 rs28087 C T 11160330 CLEC16A 3.02   10
22 (11 332) 1.45   10
22 (6611) 0.34 1.26 1.14 1.38 1.66   10
26 1.53   10
26
16 rs27908 A G 11164602 CLEC16A 3.41   10
22 (12 791) 1.35   10
22 (6247) 0.35 1.25 1.14 1.37 2.94   10
26 2.95   10
26
16 rs9941107 A G 11103542 CLEC16A 0.14 (48 753) 1.87   10
22 (8221) 0.42 0.80 0.73 0.88 3.14   10
26 3.35   10
26
5 rs1393122
d G A 4778148 LOC340094 0.38 (131 632) 2.98   10
22 (12 347) 0.17 0.74 0.66 0.85 5.09   10
26 1.10   10
24
16 rs3893660 G A 11101431 CLEC16A 0.08 (28 006) 6.71   10
23 (3441) 0.42 0.81 0.74 0.89 5.22   10
26 3.82   10
26
16 rs12922090
d T C 11322618 C16orf75 0.75 (252 825) 4.77   10
23 (2629) 0.17 0.75 0.66 0.85 6.69   10
26 1.38   10
26
9 rs2251622 T A 90013426 LOC389768 0.05 (19 677) 0.13 (49 117) 0.24 1.27 1.14 1.41 8.96   10
26 7.21   10
26
16 rs3901386 C T 11050221 CLEC16A 0.06 (20 519) 6.41   10
23 (3321) 0.41 0.81 0.74 0.89 9.63   10
26 1.02   10
25
8 rs12115114
d A G 64552434 YTHDF3 0.20 (70 026) 1.19   10
23 (994) 0.17 1.29 1.15 1.45 1.13   10
25 4.93   10
26
16 rs7198004 G A 11115118 CLEC16A 0.07 (24 701) 1.25   10
22 (5838) 0.42 0.81 0.74 0.89 1.16   10
25 6.59   10
26
16 rs7203150 C T 11115223 CLEC16A 0.12 (41 644) 1.63   10
22 (7299) 0.42 0.82 0.75 0.90 1.67   10
25 6.93   10
26
6 rs11969369
d G A 123156596 SMPDL3A 0.22 (77 478) 2.38   10
22 (10 053) 0.34 1.23 1.12 1.35 1.72   10
25 7.64   10
25
3 rs10511254
d A G 107405284 LOC728779 3.72   10
23 (1724) 7.54   10
24 (762) 0.22 0.79 0.71 0.89 5.29   10
25 1.77   10
24
2 rs10469900
d C T 38220587 C2orf58 3.96   10
22 (14 756) 3.31   10
22 (13 573) 0.21 1.24 1.12 1.38 6.24   10
25 1.32   10
24
16 rs12927773
d T G 11311464 PRM1 0.52 (177 686) 1.85   10
22 (8152) 0.17 0.77 0.68 0.88 6.53   10
25 1.29   10
25
3 rs12487092
d G T 107394865 LOC728779 1.26   10
–2(5028) 4.35   10
25 (254) 0.28 0.81 0.74 0.90 6.72   10
25 1.41   10
24
3 rs12487066
b C T 107394820 LOC728779 7.70   10
23 (3213) 4.09   10
25 (250) 0.28 0.82 0.74 0.90 8.01   10
25 1.64   10
24
18 rs4798571
d A G 7574294 PTPRM 0.41 (142 279) 0.10 (36 956) 0.16 1.27 1.13 1.43 1.02   10
24 2.72   10
25
16 rs12924729 A G 11095284 N/A 0.77 (258 378) 1.95   10
22 (8503) 0.32 0.83 0.75 0.91 1.19   10
24 1.42   10
24
2 rs10188379 C G 38224980 C2orf58 2.82   10
22 (10 594) 2.61   10
22 (10 891) 0.21 1.23 1.11 1.37 1.29   10
24 2.84   10
24
3 rs12497363 A G 107401348 LOC728779 1.03   10
22 (4181) 2.42   10
23 (1636) 0.25 0.81 0.73 0.90 1.31   10
24 6.04   10
24
3 rs13085623 G T 107415425 LOC728779 1.41   10
22 (5554) 2.71   10
23 (1778) 0.25 0.82 0.73 0.91 1.61   10
24 7.10   10
24
1 rs6696657
d T C 208584705 HHAT 0.32 (112 265) 1.71   10
22 (7643) 0.41 1.19 1.09 1.31 1.84   10
24 1.01   10
24
16 rs9746695 C T 11115395 CLEC16A 0.14 (50 787) 1.04   10
22 (4950) 0.31 0.83 0.76 0.92 1.92   10
24 1.23   10
24
1 rs305217 A G 88993060 PKN2 2.78   10
22 (10 488) 2.43   10
22 (10 220) 0.05 1.43 1.18 1.72 2.07   10
24 6.33   10
23
8 rs7005198 C G 16890680 FGF20 3.62   10
22 (13 513) 2.22   10
22 (9500) 0.20 1.23 1.10 1.37 2.10   10
24 2.51   10
24
1 rs7538427 C T 89112010 GTF2B 0.05 (19 747) 2.93   10
22 (12 168) 0.05 1.42 1.18 1.71 2.27   10
24 6.51   10
23
3 (rs12638130/rs9873496)
d,e C T 107516117 LOC728784 0.18 (64 010) 1.90   10
22 (8351) 0.45 0.85 0.77 0.92 2.43   10
24 9.49   10
24
1 rs11584383
c C T 199202489 LOC647216 0.14 (48 316) 4.62   10
23 (2557) 0.30 0.83 0.75 0.92 2.53   10
24 4.04   10
24
1 rs11102091 A G 110676947 RBM15 3.33   10
23 (1563) 0.07 (25 999) 0.44 0.84 0.77 0.92 2.63   10
24 8.61   10
24
2 rs17022137 C T 38232941 C2orf58 2.63   10
22 (9934) 0.11 (40 979) 0.21 1.22 1.09 1.35 2.86   10
24 5.69   10
24
2 rs1517440
d C T 221162118 EPHA4 0.45 (153 457) 4.94   10
22 (19 575) 0.04 1.46 1.19 1.79 2.92   10
24 7.64   10
24
11 rs4627080 G T 9292925 TMEM41B 4.69   10
22 (17 273) 0.79 (265 886) 0.07 1.35 1.15 1.59 3.02   10
24 1.41   10
23
9 rs1924219
d C T 110290167 LOC347292 1.80   10
22 (6911) 3.57   10
22 (14 546) 0.37 1.19 1.08 1.30 3.09   10
24 3.08   10
24
6 rs3800036
d G A 1705555 GMDS 1.17   10
22 (4721) 0.17 (62 606) 0.48 0.85 0.77 0.93 3.11   10
24 8.70   10
24
3 rs1447925 T C 60763882 FHIT 3.43   10
22 (12 862) 0.26 (93 782) 0.20 1.22 1.09 1.36 3.33   10
24 3.12   10
24
7 rs334517 G T 47527873 TNS3 3.73   10
22 (13 925) 0.70 (239 174) 0.44 0.85 0.78 0.93 3.35   10
24 2.10   10
24
8 rs6557618 A T 23057070 TNFRSF10D 0.11 (40 981) 4.62   10
22 (18 425) 0.29 0.83 0.75 0.92 3.93   10
24 1.05   10
23
16 rs8055544 G T 10999062 CLEC16A 0.17 (61 857) 1.25   10
22 (5841) 0.42 1.18 1.08 1.29 4.00   10
24 1.60   10
24
17 rs17758761 C A 51409524 ANKFN1 2.11   10
22 (8084) 0.88 (295 661) 0.03 1.52 1.20 1.91 4.00   10
24 1.65   10
23
1 rs12044852
b A C 116889302 CD58 1.01   10
23 (683) 3.01   10
25 (233) 0.09 0.74 0.63 0.88 4.21   10
24 1.43   10
24
1 rs1572263 G A 110687259 RBM15 3.85   10
22 (14 282) 0.06 (21 920) 0.27 0.83 0.75 0.92 4.44   10
24 2.17   10
23
8 rs3808524 C T 23217928 LOXL2 0.64 (218 362) 4.81   10
22 (19 127) 0.45 0.85 0.78 0.93 4.48   10
24 1.20   10
23
12 rs2373461 T G 100477852 MYBPC1 0.69 (233 655) 4.02   10
22 (16 201) 0.05 1.41 1.16 1.70 4.49   10
24 2.69   10
24
6 rs2326699 T G 6075217 F13A1 2.71   10
22 (10 205) 0.07 (28 846) 0.23 1.21 1.09 1.34 4.55   10
24 2.06   10
23
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CHR SNP A1 A2 BP Gene Original GWAS P-value (rank) MAF OR L95 U95 P-value HLA conditional
P-value TDT Test CMH Test
3 rs1132200
d T C 120633526 TMEM39A 0.39 (136 508) 1.35   10
23 (1071) 0.16 0.80 0.71 0.91 4.59   10
24 1.73   10
23
2 rs993598 A G 178890941 OSBPL6 0.26 (91 913) 3.08   10
22 (12 747) 0.47 1.18 1.07 1.29 4.64   10
24 1.08   10
23
2 rs17265240 G T 5193686 LOC727982 0.36 (126 348) 4.37   10
22 (17 497) 0.23 1.20 1.08 1.33 4.69   10
24 3.77   10
24
1 rs6673423 T C 110717541 SLC16A4 4.57   10
22 (16 789) 0.06 (24 690) 0.27 0.83 0.75 0.92 4.74   10
24 2.38   10
23
10 rs7088282 T G 10186238 LOC644540 0.18 (64 503) 3.23   10
22 (13 284) 0.27 1.19 1.08 1.32 5.09   10
24 1.12   10
23
1 rs17419032
d T C 199265154 KIF21B 0.16 (55 617) 2.09   10
23 (1452) 0.28 0.84 0.75 0.92 5.29   10
24 8.30   10
24
5 rs6895902
c A G 179134453 MAML1 0.19 (67 419) 2.58   10
22 (10 789) 0.33 1.18 1.08 1.30 5.46   10
24 1.90   10
23
17 rs4791872 G A 9643950 LOC644070 3.43   10
22 (12 846) 0.55 (190 684) 0.01 2.18 1.40 3.39 5.48   10
24 3.22   10
23
16 rs1646066
c C T 11226007 LOC729954 75 025 2.00   10
23 (1404) 0.14 0.79 0.69 0.90 5.49   10
24 2.92   10
24
2 rs10168171 A G 28085591 LOC728408 3.53   10
22 (13 220) 0.87 (293 624) 0.18 0.81 0.71 0.91 5.93   10
24 6.41   10
24
15 rs3825904 T G 99745948 PCSK6 4.04   10
22 (15 000) 0.95 (319 841) 0.29 1.19 1.08 1.31 6.47   10
24 1.33   10
23
1 rs12122721
d A G 199251103 KIF21B 0.28 (96 681) 5.13   10
23 (2783) 0.29 0.84 0.76 0.93 6.47   10
24 1.07   10
23
1 rs3890745
c C T 2543484 MMEL1 0.07 (27 687) 1.42   10
22 (6501) 0.31 0.84 0.77 0.93 6.78   10
24 3.32   10
24
1 rs11583328
d A G 199268796 CACNA1S 0.07 (26 214) 4.22   10
24 (581) 0.29 0.84 0.76 0.93 6.88   10
24 1.06   10
23
17 rs9904838 G A 51401320 ANKFN1 4.90   10
23 (2163) 0.46 (159 737) 0.04 1.45 1.17 1.81 7.10   10
24 3.02   10
23
3 rs1907878
d G A 104487162 LOC644681 0.65 (221 976) 2.91   10
22 (12 074) 0.12 1.26 1.10 1.43 7.36   10
24 1.81   10
23
2 rs10180107 T C 28094029 LOC728408 4.25   10
22 (15 765) 0.81 (274 882) 0.18 0.81 0.72 0.92 7.40   10
24 8.53   10
24
16 rs4451969
c T C 11291020 PRM1 0.33 (114 085) 4.27   10
22 (17 113) 0.33 0.85 0.77 0.93 7.49   10
24 1.08   10
24
10 rs4746479 A G 66399352 ANXA2P3 0.36 (124 519) 3.68   10
22 (14 991) 0.17 1.22 1.09 1.37 7.60   10
24 2.21   10
23
16 rs2280381 C T 84576134 IRF8 0.91 (304 941) 1.71   10
22 (7626) 0.37 0.85 0.77 0.93 7.72   10
24 8.96   10
23
6 rs7742658 A C 28708471 LOC646160 7.17   10
23 (2988) 0.15 (54 805) 0.02 1.73 1.26 2.37 7.77   10
24 4.86   10
24
3 rs1304118 T C 104472940 LOC644681 0.33 (116 314) 2.41   10
22 (10 186) 0.12 1.26 1.10 1.43 7.79   10
24 2.29   10
23
11 rs2515795 A G 117322486 TMPRSS13 0.57 (193 175) 5.32   10
23 (2855) 0.42 1.16 1.07 1.27 8.17   10
24 4.07   10
24
11 rs17118741 A G 115118181 LOC283143 4.95   10
22 (18 214) 0.56 (193 709) 0.09 1.28 1.11 1.48 8.59   10
24 8.07   10
24
2 rs10196846 A C 38232614 C2orf58 6.04   10
23 (2589) 1.34   10
22 (6196) 0.15 1.23 1.09 1.39 8.62   10
24 1.03   10
23
3 rs1373737 T G 107341020 LOC728779 0.17 (59 505) 2.44   10
23 (1645) 0.36 0.85 0.77 0.94 8.64   10
24 9.96   10
24
9 rs1886106 A G 110208464 LOC347292 0.07 (26 513) 4.08   10
22 (16 425) 0.33 1.17 1.07 1.29 9.12   10
24 7.41   10
24
3 rs9855065
d A G 120612831 CDGAP 0.76 (255 088) 2.83   10
22 (11 781) 0.18 0.82 0.72 0.92 9.14   10
24 3.46   10
23
14 rs7160860
c T C 53409243 BMP4 0.92 (308 800) 2.69   10
26 (177) 0.13 1.24 1.09 1.41 9.16   10
24 3.71   10
24
12 rs10777873 T C 96404189 LOC643711 0.66 (223 145) 1.20   10
22 (5644) 0.17 0.81 0.72 0.92 9.16   10
24 4.93   10
24
22 rs134547 G A 27131009 TTC28 0.26 (91 630) 2.02   10
22 (8770) 0.11 0.78 0.67 0.90 9.39   10
24 2.97   10
23
23 rs11092309 A G 100624381 ARMCX4 0.26 (91 845) 1.15   10
22 (5449) 0.37 1.19 1.07 1.32 9.48   10
24 1.09   10
23
1 rs11208363 G A 40783041 ZNF684 0.08 (28 126) 3.48   10
22 (14 195) 0.15 0.80 0.70 0.91 9.49   10
24 1.63   10
23
3 rs1025984 G C 145238877 C3orf58 4.51   10
22 (16 588) 0.62 (212 857) 0.34 1.17 1.07 1.28 9.49   10
24 7.39   10
24
14 rs4247039 A G 104095559 LOC400258 0.13 (46 192) 0.07 (25 366) 0.18 0.81 0.72 0.92 9.59   10
24 6.65   10
24
5 rs7720899 A G 123907793 ZNF608 3.00   10
22 (11 248) 0.08 (30 658) 0.10 1.27 1.10 1.47 9.97   10
24 1.65   10
23
CHR, chromosome; A1, minor allele; A2, major allele; BP, physical base pair location of SNP in build 36; TDT, transmission disequilibrium test; CMH, Cochran–Mantel–Haenszel test; MAF, minor allele
frequency; OR, odds ratio(relative to theminorallele);L95/U95, lower andupper boundsof the 95% conﬁdence interval for the OR. Alleles are speciﬁed with respect to the forward (þ)strand of the National
Center for Biotechnology Information’s Build 36.
aHLA-DRB1 1501 tag SNP.
bSNPs which were previously examined as part of the original GWAS replication effort (1).
cSNPs also selected for parallel IMSGC studies (data for these markers may also be reported as part of other hypothesis-driven work).
dSNPs selected for Stage 2 follow-up.
eThere is one SNP for which the dbSNP ‘snp_id’ was merged into a new ‘rsID’ since the publication of the original GWAS (previous rsID/current rsID).
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5Table 2. Stage 2 follow-up results and combined analysis
Original GWAS Stage 1 follow-up Stage 2 follow-up Combined
931 family
trios
Case subjects from
931 trios versus 2431
control subjects
(1343 cases/3577 controls) (2164 cases/2016 controls) (931 trios, 3507 cases, 8024 controls)
CHR SNP A1 A2 BP Gene MAF TDT
(P-value)
CMH (P-value) MAF OR L95 U95 P-value HLA
conditional
P-value
MAF OR L95 U95 P-value HLA
conditional
P-value
MAF OR L95 U95 P-value HLA
conditional
P-value
1 rs12122721 A G 199251103 KIF21B 0.28 0.28 5.13   10
23 0.29 0.84 0.76 0.93 6.47   10
24 1.07   10
23 0.26 0.85 0.77 0.94 1.88   10
23 4.10   10
23 0.28 0.82 0.77 0.88 6.56   10
210 2.61   10
29
5 rs1393122 G A 4778148 LOC340094 0.17 0.38 2.98   10
22 0.17 0.74 0.66 0.85 5.09   10
26 1.10   10
24 0.16 0.94 0.83 1.06 0.28 0.37 0.17 0.80 0.74 0.86 3.28   10
29 1.89   10
26
3 rs1132200 T C 120633526 TMEM39A 0.14 0.39 1.35   10
23 0.16 0.80 0.71 0.91 4.59   10
24 1.73   10
23 0.15 0.79 0.70 0.89 1.74   10
24 1.52   10
25 0.16 0.80 0.74 0.87 3.09   10
28 1.93   10
28
16 rs12922090 T C 11322618 C16orf75 0.15 0.75 4.77   10
23 0.17 0.75 0.66 0.85 6.69   10
26 1.38   10
26 0.16 0.82 0.73 0.93 1.21   10
23 7.68   10
24 0.17 0.81 0.75 0.88 5.34   10
28 1.69   10
27
16 rs243315 T C 11292512 PRM1 0.18 0.47 3.42   10
22 0.20 0.75 0.67 0.84 1.51   10
26 3.20   10
27 0.19 0.85 0.76 0.95 3.70   10
23 1.30   10
23 0.19 0.83 0.77 0.89 1.07   10
27 6.34   10
28
1 rs11583328 A G 199268796 CACNA1S 0.27 0.07 4.22   10
24 0.29 0.84 0.76 0.93 6.88   10
24 1.06   10
23 0.28 0.89 0.81 0.98 1.41   10
22 2.85   10
22 0.29 0.86 0.81 0.92 1.79   10
26 1.17   10
26
1 rs17419032 T C 199265154 KIF21B 0.28 0.16 2.09   10
23 0.28 0.84 0.75 0.92 5.29   10
24 8.30   10
24 0.28 0.90 0.81 0.98 2.24   10
22 4.38   10
22 0.29 0.86 0.81 0.92 1.95   10
26 9.89   10
27
6 rs3800036 G A 1705555 GMDS 0.47 1.17   10
22 0.17 0.48 0.85 0.77 0.93 3.11   10
24 8.70   10
24 0.47 0.94 0.86 1.02 0.13 0.20 0.48 0.88 0.83 0.93 3.03   10
26 4.09   10
23
2 rs10469900 C T 38220587 C2orf58 0.20 3.96   10
22 3.31   10
22 0.21 1.24 1.12 1.38 6.24   10
25 1.32   10
24 0.21 1.14 1.03 1.27 1.36   10
22 9.66   10
23 0.21 1.16 1.09 1.24 1.24   10
25 3.19   10
24
16 rs12927773 T G 11311464 PRM1 0.15 0.52 1.85   10
22 0.17 0.77 0.68 0.88 6.53   10
25 1.29   10
25 0.16 0.83 0.73 0.93 1.40   10
23 9.77   10
24 0.16 0.85 0.79 0.91 1.56   10
25 1.47   10
25
3 rs10511254 A G 107405284 LOC728779 0.22 3.72   10
23 7.54   10
24 0.22 0.79 0.71 0.89 5.29   10
25 1.77   10
24 0.22 0.93 0.84 1.03 0.18 0.2 0.23 0.87 0.81 0.93 2.60   10
25 6.87   10
26
18 rs4798571 A G 7574294 PTPRM 0.16 0.41 0.10 0.16 1.27 1.13 1.43 1.02   10
24 2.72   10
25 0.16 1.04 0.93 1.17 0.49 0.49 0.16 1.16 1.08 1.25 6.88   10
25 7.66   10
25
3 (rs12638130/
rs9873496)
C T 107516117 LOC728784 0.44 0.18 1.90   10
22 0.45 0.85 0.77 0.92 2.43   10
24 9.49   10
24 0.44 0.94 0.86 1.03 0.17 0.09 0.45 0.89 0.85 0.95 7.34   10
25 3.91   10
25
3 rs12487092 G T 107394865 LOC728779 0.27 1.26   10
22 4.35   10
25 0.28 0.81 0.74 0.90 6.72   10
25 1.41   10
24 0.28 0.95 0.86 1.04 0.25 0.17 0.28 0.88 0.83 0.94 9.23   10
25 1.14   10
25
6 rs11969369 G A 123156596 SMPDL3A 0.35 0.22 2.38   10
22 0.34 1.23 1.12 1.35 1.72   10
25 7.64   10
25 0.33 1.07 0.97 1.17 0.17 0.37 0.34 1.11 1.05 1.17 4.72   10
24 2.36   10
23
2 rs1517440 C T 221162118 EPHA4 0.04 0.45 4.94   10
22 0.04 1.46 1.19 1.79 2.92   10
24 7.64   10
24 0.05 0.94 0.77 1.15 0.56 0.26 0.05 1.18 1.04 1.34 1.12   10
22 2.56   10
22
9 rs1924219 C T 110290167 LOC347292 0.35 1.80   10
22 3.57   10
22 0.37 1.19 1.08 1.30 3.09   10
24 3.08   10
24 0.35 1.02 0.93 1.12 0.67 0.99 0.36 1.07 1.01 1.13 1.89   10
22 0.12
3 rs1907878 G A 104487162 LOC644681 0.13 0.65 2.91   10
22 0.12 1.26 1.10 1.43 7.36   10
24 1.81   10
23 0.12 0.94 0.83 1.08 0.39 0.32 0.12 1.08 1.00 1.17 0.06 3.91   10
22
1 rs6696657 T C 208584705 HHAT 0.42 0.32 1.71   10
22 0.41 1.19 1.09 1.31 1.84   10
24 1.01   10
24 0.42 0.91 0.83 0.99 2.53   10
22 3.83   10
22 0.41 1.05 0.99 1.11 0.08 5.18   10
23
CHR, chromosome; A1, minor allele; A2, major allele; BP, physical base pair location of SNP in build 36; MAF, minor allele frequency; OR, odds ratio (relative to the minor allele); L95/U95, lower and upper bounds of the 95% conﬁdence interval for the OR. Alleles are
speciﬁed with respect to the forward (þ) strand of the National Center for Biotechnology Information’s Build 36.
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7protein (KLP) involved in neuronal (axonal) transport. Its
uniqueness stems from its enrichment in dendrites compared
with the typical cell body and from its contrast from other
plus end-directed KLPs, which have axon enrichment (16).
KIF21B is also expressed in a variety of immune cells.
Although KIF21B has not been functionally associated with
neurodegeneration or inﬂammation, given the nature and
role of its protein in neurons, there is a plausible biologic
role for this gene in MS. Recently, another kinesin superfamily
member (KIF1B) was reported as associated with MS (17);
however, efforts by the IMSGC have failed to conﬁrm this
association (IMSGC, unpublished data). KIF21B is among
the ﬁrst genes identiﬁed via association studies, with the
potential for a direct neurodegenerative role in MS pathology.
Very little has been known about TMEM39A (mRNA-
transmembrane protein 39A). The associated SNP (rs1132200)
within this gene causes a non-synonymous amino acid change
(alanine–threonine) at position 487 in the protein. Although
this SNP may hold some functional effect relevant to MS,
almost nothing is known about this gene and what biologic
role it might play with regard to disease susceptibility.
PRM1 (protamine 1) functions as a DNA-binding protein
expressed in the nucleus of sperm. The strongest association
in this region is with rs243315 and is 50 of PRM1; however,
there are several SNPs across this region of chromosome 16
showing mild-to-moderate levels of signiﬁcance within the
top hits (rs12922090, rs243315, rs1292773) (Table 2). This
region of chromosome 16 is .100 kb from CLEC16A and
there is little-to-no LD between these SNPs and any SNP
within CLEC16A. There is, however, a very nearby candidate
gene, SOCS1 (suppressor of cytokine signaling 1), which is in
strong LD with these SNPs and could possibly contain the
true association. Additional work is needed to explore the
exact location of this association, and is the focus of ongoing
laboratory efforts.
Through this exhaustive follow-up approach, we have ident-
iﬁed a number of additional MS susceptibility loci and high-
lighted even more loci that may yet prove to be involved in
MS. Ultimately, ﬁne mapping and functional studies will be
required to understand the consequences of the associations
detected in this experiment.
MATERIALS AND METHODS
Case and control subjects
Stage 1 follow-up. DNA samples from study participants were
ascertained at two sites within the USA [Brigham and
Women’s Hospital in Boston (BWH) and the University of
California at San Francisco (UCSF)] and through one site in
the UK [University of Cambridge (CMS)]. All affected indi-
viduals met the McDonald criteria for a positive diagnosis
for MS (18). Unrelated controls were obtained from these
US sites and from the British 1958 Birth Cohort Study.
These controls were selected to provide nearly equivalent
gender and age matching. This sample set contained 2961
individuals (1479 cases and 1482 controls) for genotyping.
Additional control sample data were available on 2198
samples from both the National Institute of Mental Health
(NIMH) and the Wellcome Trust Case Control Consortium
(WTCCC). Data from these additional controls were pre-
viously analyzed in the 110 SNPs selected for replication in
the original GWAS (1). With the exception of a small set of
overlapping SNPs genotyped in this effort (95 of the 110
SNPs from the replication phase of the original GWAS were
genotyped and analyzed in this study), these control data are
completely independent of previous association testing in
these MS samples. All samples used in the Stage 1 analysis
come from participants self-reporting as non-Hispanic whites
(Table 4).
Table 3. MS susceptibility genes outside of the MHC
CHR SNP BP Gene Original GWAS P-value (rank)
a Meta-analysis CMH test P-value (rank)
b
TDT test CMH test
1 rs12044852
c 116889302 CD58 1.01   10
23 (683) 3.01   10
25 (233) 1.48   10
27 (2242)
10 rs2104286 6139051 IL2RA 3.29   10
23 (1549) 2.85   10
24 (479) 1.52   10
26 (2639)
3 rs1132200 120633526 TMEM39A
d 0.39 (136 508) 1.35   10
23 (1071) 1.33   10
22 (48 639)
11 rs2074229
c 60539684 CD6 0.07 (26 233) 4.01   10
23 (2317) 4.05   10
25 (3580)
1 rs12122721 199251103 KIF21B
d 0.28 (96 681) 5.13   10
23 (2783) 2.13   10
23 (12 750)
16 rs6498169
c 11156830 CLEC16A 2.91   10
22 (10 940) 6.51   10
23 (3363) 1.83   10
24 (4638)
1 rs3890745
c 2543484 MMEL1
e 0.07 (27 687) 1.42   10
22 (6501) 0.05 (163 561)
5 rs6897932 35910332 IL7R 5.83   10
23 (2497) 1.65   10
22 (7399) 7.71   10
26 (3020)
16 rs2280381
c 84576134 IRF8 0.91 (304 941) 1.71   10
22 (7626) 5.08   10
24 (6277)
16 rs243315 11292512 PRM1
d 0.47 (160 855) 3.42   10
22 (13 992) 1.50   10
22 (53 859)
19 rs280500
c 10351402 TYK2 0.33 (116 121) 0.08 (31 423) 0.29 (770 374)
12 rs4149623
c 6320839 TNFRSF1A 0.38 (133 155) 0.14 (52 423) 9.99   10
26 (3 084)
f
18 rs4891786
c 65722590 CD226 0.12 (42 656) 0.79 (265 756) 0.85 (2 175 710)
SNPs are sorted by P-value rank in the CMH test from the original GWAS.
CHR, chromosome; BP, physical base pair location of SNP in build 36; TDT, transmission disequilibrium test; CMH, Cochran–Mantel–Haenszel test.
aOriginal GWAS ranking is out of a total of 334 923 SNPs.
bMeta-analysis ranking is out of a total of 2.56 million SNPs. This work was previously published (11).
cMost signiﬁcant SNP within each locus in the original GWAS (this is not necessarily the strongest associated SNP within the locus, as identiﬁed by other ﬁne
mapping efforts).
dSNPs identiﬁed with genome-wide signiﬁcance in this study.
eBan et al. (unpublished data) suggest that MMEL1 is another MS susceptibility gene.
fThese results are for rs767455 (only 367 base pairs from rs4149623) not for rs4149623 (as rs4149623 was not included in the meta-analysis data set).
958 Human Molecular Genetics, 2010, Vol. 19, No. 5Stage 2 follow-up. Cases and controls genotyped for Stage 2
were made available through an entirely independent replica-
tion set (11). This data set consists of an additional 2164 cases
and 2016 controls from the sites listed previously as well as
those made available through other collaborative efforts. The
same criteria were applied to these cases and controls as in
Stage 1 (Table 5).
Approval for these studies was granted by the appropriate
institutional review boards. All studies were performed after
informed consent from human subjects.
Molecular analysis
Stage 1 follow-up. We utilized the Illumina iSelect Custom
BeadChip platform to perform additional genotyping of a
more in-depth list of top hits from the GWAS experiment
(19). This experiment was performed in parallel with several
Table 4. Demographic characteristics of Stage 1 follow-up cases and controls
Stage 1 data set (1343 cases/1379 controls) Additional controls (2198 controls)
a
UK USA UK USA (NIMH)
Case Control Case Control UKBS 1958 BC
Gender (count)
Female 493 570 343 329 360 359 344
Male 181 194 326 286 378 378 379
Ratio (female–male) 2.72 2.94 1.05 1.15 0.95 0.95 0.91
Total individuals 674 764 669 615 738 737 723
Age at analysis (years)
Average 50.0 50.0 50.0 48.5 Unknown 50.0 Unknown
Range 27–72 50 23–89 23–84 18–69 50 Unknown
Age at onset (years)
Average 32.3 NA 33.9 NA NA NA NA
Range 9–57 NA 4–64 NA NA NA NA
Disease course (%)
Relapsing remitting 55.04 NA 49.93 NA NA NA NA
Secondary progressive 28.49 NA 17.94 NA NA NA NA
Primary progressive 13.65 NA 10.16 NA NA NA NA
Progressive relapsing 0 NA 2.99 NA NA NA NA
Clinically isolated syndrome 0 NA 6.72 NA NA NA NA
Unknown 2.82 NA 12.26 NA NA NA NA
Expanded disability status scale score (%)
,3 35.61 NA 46.34 NA NA NA NA
3t o,6 23.29 NA 20.78 NA NA NA NA
6 15.58 NA 7.77 NA NA NA NA
6.5 8.75 NA 5.38 NA NA NA NA
.6.5 15.13 NA 7.17 NA NA NA NA
Unknown 1.63 NA 12.56 NA NA NA NA
UKBS, UK Blood Services; 1958 BC, British 1958 Birth Cohort; NIMH, National Institute of Mental Health.
aThese control data were provided by both the NIMH and the WTCCC and represent the 723 US controls and the 1475 UK controls (respectively) used in the 110
SNP replication analysis of our original screen (1).
Table 6. SNPs selected for Stage 1 follow-up genotyping (out of 334 923 ana-
lyzed in original GWAS)
SNP
count
Description
62 488 SNPs P   0.10 in either TDT or CMH screening
35 928 SNPs P   0.10 in TDT screening
37 929 SNPs P   0.10 in CMH screening
11 369 SNPs P   0.10 in both TDT and CMH screening
33 484
a SNPs chosen for Illumina iSelect Inﬁnium design for Stage 1
30 915 SNPs arrayed on the beadchip for Stage 1
30 392 SNPs passing primary QC for Stage 1
831 Additional SNPs dropped through secondary QC
1 HLA-tag SNP (rs3135388)
95 SNPs previously genotyped for initial GWAS replication effort
(n ¼ 95/110)
28 696 SNPs exclusively selected for Stage 1
769 SNPs overlapping Stage 1 and parallel IMSGC projects
aThis reﬂects those SNPs likely to generate accurate and reliable assays using
the Illumina platform.
Table 5. Stage 2 follow-up cases and controls
Stage 2 data set
a
Collection USA UK Total
BWH WU ACP UCSF RUSH UC 1958 BC
Cases 224 158 588 363 0 831 0 2164
Controls 405 13 36 30 513 0 1019 2016
Total 4180
BWH,BrighamandWomen’sHospital;WU, Washington University,St Louis;
ACP, Accelerated Cure Project; UCSF, University of California,
San Francisco; RUSH, RUSH University; UC, University of Cambridge; 1958
BC, British 1958 Birth Cohort.
aThis data set has previously been described in detail (11) and represents an
independent set of cases and controls from those used in either the original
GWAS or the Stage 1 follow-up.
Human Molecular Genetics, 2010, Vol. 19, No. 5 959other projects organized through the IMSGC to maximize the
use of samples and resources. This strategy allowed us to use
the maximum number of bead types (60 800) available for the
iSelect platform (depending on the chemistry used for assay-
ing a particular SNP, there may be one bead type per SNP
or two bead types per SNP). The SNPs selected for inclusion
in our Stage 1 effort satisﬁed two criteria: (i) SNPs demon-
strating P-values  0.10 in either the TDT or the CMH test,
from the original GWAS screen; (ii) SNPs that had an Inﬁ-
nium score .0.60 (a proprietary score used by Illumina to
determine the likelihood of assays to generate accurate and
reliable results). In the original GWAS, a total of 62 488
SNPs had a P-value  0.10 in either the TDT or CMH test;
of these, 33 484 had an Inﬁnium quality score .0.60. These
33 484 SNPs were selected for inclusion in Stage 1 of our
replication effort along with an additional 19 318 SNPs (for
other parallel IMSGC projects) giving a total of 52 801
SNPs (60 800 bead types). Once manufacturing and internal
QC procedures at Illumina were complete, 48 767 SNPs
(92% of the total requested) were arrayed on each of the
beadchips for genotyping, including 30 915 of the Stage 1
follow-up SNPs (49% of those meeting the initial criteria)
(Table 6). A total of 29 561 of these 30 915 SNPs were ulti-
mately analyzed after QC procedures were completed.
Through LD (r
2 ¼ 0.80), these 29 561 SNPs capture 60.1%
of the total SNPs (62 488) having a P-value  0.10 in the orig-
inal GWAS. Furthermore, these SNPs, through LD (r
2 ¼
0.80), cover 92% of all the SNPs with P-values  0.05 in
the original screen. Supplementary Material, Figure S2 pro-
vides a visual summary of those SNPs analyzed in Stage 1
relative to their signiﬁcance in the original GWAS and of
those SNPs further chosen and analyzed in Stage 2.
We followed the Illumina Inﬁnium protocol for the geno-
typing of DNA samples. In brief, this involved ampliﬁcation
and subsequent fragmentation of genomic DNA, followed by
hybridization of this fragmented DNA to the BeadChip, then
an extension step and ﬁnally imaging to read the chip (19).
We genotyped an initial data set of 2961 individuals (1479
cases and 1482 controls) distributing DNA samples across
beadchips (12 samples per beadchip), with attention given to
representing both cases and controls from each of the different
ascertainment sites on every chip as to minimize any exper-
imental biases in genotyping performance.
Stage 2 follow-up. Following the analysis for Stage 1, there
were 85 SNPs outside of the MHC region with association
P-values  0.001, and of these, we genotyped 20 SNPs in a
second independent data set (independent of both Stage 1
and the original GWAS) for our Stage 2 follow-up. There
were ﬁve criteria used to select the SNPs for Stage 2 genotyp-
ing: (i) Stage 1 P-value  0.001; (ii) SNPs within or nearby
known genes; (iii) exclusion of SNPs in the MHC (within
29–34 Mb on chromosome 6); (iv) exclusion of SNPs overlap-
ping with previously identiﬁed MS genes or examined as part
of the initial GWAS replication effort; (v) exclusion of SNPs
being analyzed as part of other parallel projects using this
common data set. We chose 21 SNPs that met these criteria;
however, one SNP (rs9855065) failed to pass the design
process. We used the Sequenom MassARRAY iPLEX plat-
form for this genotyping. The Sequenom protocol involves a
multiplex PCR reaction prior to a single-base primer extension
reaction. The individual SNPs are identiﬁed by using matrix-
assisted laser desorption/ionization time-of-ﬂight mass spec-
trometry (20).
Statistical analysis
Stage 1 follow-up. We initially performed a thorough series of
QC procedures, which are described in the Supplemental
Material. Following stringent QC and ﬁnding no signiﬁcant
population differences in this data set, we chose to analyze
this data set as one uniform sample collection (Supplementary
Material, Fig. S3). The Stage 1 test for association was con-
ducted using a logistic regression approach as implemented
in PLINK and using PCA1 and PCA2 as covariates to
correct for differential genotyping bias (21). This method
tests for a linear trend in the number of alleles at a single
locus. This analysis included GWAS data from 2198 NIMH
and WTCCC controls used in the original GWAS replication
in addition to the newly genotyped data set of 1343 cases
and 1379 controls. After removing SNPs from the MHC (i.e.
29–34 Mb on chromosome 6), the genomic inﬂation factor
(GIF) was 1.16 (Supplementary Material, Fig. S4). This is
larger than the original GWAS GIF (1.05) and is likely due
to preferential selection of SNPs with small P-values. In
addition to the standard logistic regression, a conditional logis-
tic regression analysis was also performed conditioning on the
HLA-DRB1 1501 tag SNP (rs3135388). Genotypes for
rs3135388 had previously been imputed for the NIMH and
WTCCC control, as this SNP was not genotyped on the Affy-
metrix 500K chip.
Stage 2 follow-up. PLINK was also used for the Stage 2 repli-
cation analysis. Logistic regression was used to test for associ-
ation with the 19 SNPs and 4180 independent replication
samples that passed QC. To perform a joint analysis of both
Stage 1 and Stage 2 data sets, and the original GWAS
screen (931 trios and 2431 controls), the UNPHASED soft-
ware was utilized (22). A joint conditional analysis was also
done on the HLA-tag SNP (rs3135388) in UNPHASED.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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